Efficacy and Safety of Canagliflozin in Patients with Type 2 Diabetes and Stage 3 Nephropathy

Hala Yamout, Vlado Perkovic, Melanie Davies, Vincent Woo, Dick de Zeeuw, Cristiana Mayer, Ujjwala Vijapurkar, Irina Kline, Keith Usiskin, Gary Meininger, George Bakris*

*Bijbehorende auteur voor dit werk

OnderzoeksoutputAcademicpeer review

99 Citaten (Scopus)
99 Downloads (Pure)

Samenvatting

Background/Aims: Some sodium glucose co-transporter 2 (SGLT2) inhibitors are approved for the treatment of patients with type 2 diabetes mellitus (T2DM) with an estimated glomerular filtration rate (eGFR) of >= 45 ml/mm/1.73 m(2). The efficacy and safety of canagliflozin, an approved SGLT(2) inhibitor, was evaluated in patients with stage 3 chronic kidney disease (CKD; eGFR >= 30 to = 45 and = 30 and

Originele taal-2English
Pagina's (van-tot)64-74
Aantal pagina's11
TijdschriftAmerican Journal of Nephrology
Volume40
Nummer van het tijdschrift1
DOI's
StatusPublished - 2014

Vingerafdruk

Duik in de onderzoeksthema's van 'Efficacy and Safety of Canagliflozin in Patients with Type 2 Diabetes and Stage 3 Nephropathy'. Samen vormen ze een unieke vingerafdruk.

Citeer dit